A recent study led by the Alzheimer Center Amsterdam, Amsterdam UMC, and Combinostics found that the new cCOG tool is comparable to traditional pen-and-paper neuropsychology tests in detecting MCI and dementias.
Alzheimer's proteins in the cerebrospinal fluid play an increasingly important role in an accurate diagnosis. In this article, Dr. Hanneke Rhodius-Meester of the Alzheimer Center Amsterdam explains how cDSI can help doctors decide which patients are appropriate for a lumbar puncture.
Combinostics is pleased to announce the closure of a €3.9M series A funding round to extend the company's cNeuro platform in the US and Asia.
Combinostics is pleased to announce an exclusive partnership with Nihon Medi-Physics to develop and market the cNeuro platform in Japan.
Three peer-reviewed, scientific journals have published articles that describe the use of the cNeuro platform for dementias and other cognitive disorders.
Combinostics has been selected to join the 2019 MassChallenge HealthTech cohort which represents the most innovative technologies advancing health and improving the overall patient experience.
Combinostics is pleased to announce the release of version 1.4.0 of the cNeuro suite of tools. The upgrade provides new access to cMRI features and features improved classification algorithms in cDSI.
Combinostics and Siemens Healthineers are partnering to distribute Combinostic’s cNeuro cMRI application through the Siemens Healthineers Digital Ecosystem.
The US FDA has issued 510(k) clearance for Combinostic's image quantification software cNeuro cMRI.
Combinostics received a start-up award at the Future X Healthcare event, organized by Roche.